Insider · CIK 0001753055

Hickey Benjamin

Reports to the SEC for 5 companies · PRINCETON, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001753055

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsA Award	President, RayzeBio Org.	AAward	+11.4K sh	—	—	11,429
2026-03-10	BMYBRISTOL MYERS SQUIBB CO · Performance SharesA Award	President, RayzeBio Org.	AAward	+17.1K sh	—	—	17,143
2026-02-27	BMYBRISTOL MYERS SQUIBB COF Tax Payment	President, RayzeBio Org.	FTax Payment	−1,672 sh	$62.37	−$104K	16,672
2026-02-27	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	President, RayzeBio Org.	MExercise/Conversion	+3,286 sh	—	—	18,344
2026-02-27	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	President, RayzeBio Org.	MExercise/Conversion	−3,286 sh	—	—	3,286
2026-02-01	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	President, RayzeBio Org.	MExercise/Conversion	−10.1K sh	—	—	10,079
2026-02-01	BMYBRISTOL MYERS SQUIBB COF Tax Payment	President, RayzeBio Org.	FTax Payment	−3,810 sh	$55.05	−$210K	15,058
2026-02-01	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	President, RayzeBio Org.	MExercise/Conversion	+10.1K sh	—	—	18,868
2025-12-05	Mural Oncology plcStock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−8,462 sh	—	—	0
2025-12-05	Mural Oncology plcStock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2025-12-05	Mural Oncology plcStock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−8,637 sh	—	—	0
2025-06-11	Mural Oncology plcStock Option (right to buy)A Award	Director	AAward	+8,637 sh	—	—	8,637
2025-05-09	BMYBRISTOL MYERS SQUIBB COS Sale	President, RayzeBio Org.	SSale	−97.391 sh	$38.01	−$3,701.832	0
2025-03-10	BMYBRISTOL MYERS SQUIBB CO · Performance SharesA Award	President, RayzeBio Org.	AAward	+20.1K sh	—	—	20,084
2025-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsA Award	President, RayzeBio Org.	AAward	+13.4K sh	—	—	13,389
2025-03-01	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	President, RayzeBio Org.	MExercise/Conversion	−3,286 sh	—	—	6,572
2025-03-01	BMYBRISTOL MYERS SQUIBB COF Tax Payment	President, RayzeBio Org.	FTax Payment	−1,630 sh	$59.62	−$97.2K	8,789
2025-03-01	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	President, RayzeBio Org.	MExercise/Conversion	+3,286 sh	—	—	10,419
2025-02-01	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	President, RayzeBio Org.	MExercise/Conversion	−10.1K sh	—	—	20,158
2025-02-01	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	President, RayzeBio Org.	MExercise/Conversion	+10.1K sh	—	—	10,858
2025-02-01	BMYBRISTOL MYERS SQUIBB COF Tax Payment	President, RayzeBio Org.	FTax Payment	−3,725 sh	$58.95	−$220K	7,133
2024-05-30	Mural Oncology plcStock Option (right to buy)A Award	Director	AAward	+8,462 sh	—	—	8,462
2024-05-30	Mural Oncology plcStock Option (right to buy)A Award	Director	AAward	+8,462 sh	$3.35	+$28.3K	8,462
2024-03-10	BMYBRISTOL MYERS SQUIBB CO · Performance SharesA Award	President, RayzeBio Org.	AAward	+5,805 sh	—	—	5,805
2024-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsA Award	President, RayzeBio Org.	AAward	+3,870 sh	—	—	3,870
2024-03-01	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsA Award	President, RayzeBio Org.	AAward	+9,858 sh	—	—	9,858
2024-01-23	Mirati Therapeutics, Inc.D Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−17K sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−2,128 sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−43.3K sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.D Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−27.8K sh	—	—	89,227
2024-01-23	Mirati Therapeutics, Inc.D Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−72.2K sh	—	—	17,021
2024-01-16	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−631 sh	$59.02	−$37.2K	117,028
2024-01-16	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−966 sh	$59.02	−$57K	117,659
2024-01-08	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−2,090 sh	$58.92	−$123K	118,625
2023-12-29	Mirati Therapeutics, Inc.A Award	EVP, Chief Commercial Officer	AAward	+17K sh	$58.75	+$1M	120,715
2023-12-14	Mural Oncology plcStock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,021
2023-12-13	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−2,220 sh	$56.67	−$126K	103,694
2023-08-09	Mirati Therapeutics, Inc.A Award	EVP, Chief Commercial Officer	AAward	+22.3K sh	$37.00	+$825K	105,914
2023-01-20	Mirati Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	EVP, Chief Commercial Officer	AAward	+45.5K sh	—	—	45,456
2023-01-20	Mirati Therapeutics, Inc.A Award	EVP, Chief Commercial Officer	AAward	+36.4K sh	—	—	83,617
2023-01-17	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−619 sh	$42.38	−$26.2K	47,223
2023-01-17	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−947 sh	$42.38	−$40.1K	47,842
2023-01-09	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−2,088 sh	$45.37	−$94.7K	48,789
2022-12-21	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−3,248 sh	$40.41	−$131K	50,877
2022-12-19	Mirati Therapeutics, Inc.A Award	EVP, Chief Commercial Officer	AAward	+19.1K sh	—	—	54,125
2022-06-08	Surface Oncology, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+24K sh	—	—	24,000
2022-01-18	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−627 sh	$120.48	−$75.5K	34,976
2022-01-14	Mirati Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	EVP, Chief Commercial Officer	AAward	+17.8K sh	—	—	17,821
2022-01-14	Mirati Therapeutics, Inc.A Award	EVP, Chief Commercial Officer	AAward	+10.8K sh	—	—	35,603
2022-01-07	Mirati Therapeutics, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−1,964 sh	$135.94	−$267K	24,848

Recent filings

Accepted (ET)
Mar 124
Hickey Benjamin0001753055-26-000006
SEC(opens sec.gov)
Mar 34
Hickey Benjamin0001753055-26-000004
SEC(opens sec.gov)
Feb 34
Hickey Benjamin0001753055-26-000002
SEC(opens sec.gov)
Dec 54
Hickey Benjamin0001193125-25-308804
SEC(opens sec.gov)
Jun 134
Hickey Benjamin0000950170-25-085817
SEC(opens sec.gov)
May 134
Hickey Benjamin0000014272-25-000097
SEC(opens sec.gov)
Mar 124
Hickey Benjamin0000014272-25-000062
SEC(opens sec.gov)
Mar 44
Hickey Benjamin0000014272-25-000045
SEC(opens sec.gov)
Feb 44
Hickey Benjamin0000014272-25-000014
SEC(opens sec.gov)

Companies

Address

BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 AND PROVINCE LINE ROAD

PRINCETON, NJ, 08543